Loading market dashboard
Noveris Health Sciences Inc.
MYCOFHealthcareOTCCA
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
VANCOUVER, BC, Canada, June 5, 2026 – TheNewswire — Noveris Health Sciences Inc. (CSE: NVRS | FSE: 0NF0 | OTC: MYCOF) (“Noveris” or the “Company”) is pleased to provide this corporate update. Re-Engagement with Applied Pharmaceutical Innovation
Vancouver, British Columbia – TheNewswire - April 29, 2026 – Noveris Health Sciences Inc. (the “ Company ”, or “ Noveris ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) wishes to provide a corporate update. Noveris is a biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. Following completion of the Company's debt restructuring, and its recent successful financing for gross proceeds of CDN $2.3 million, the Company now intends to focus on two primary business objectives: (1) commercializing its patent portfolio, and (2) developing and commercializing therapies and technologies based on stem cell biology.
Vancouver, British Columbia, April 22, 2026 - TheNewswire – Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce that it has entered into an advisory agreement (the “ Agreement ”) with DS Market Solutions Inc. (“ DSMS ”), pursuant to which DSMS will provide liquidity and stability services to the Company in accordance with the policies of the Canadian Securities Exchange. Pursuant to the Agreement, DSMS will assist in entering orders, including bidding and offering, and will provide the Company with information regarding trading patterns in its securities on the CSE, as well as reports on services performed by DSMS. DSMS will receive compensation of $10,000 per month (plus applicable taxes). The engagement will become effective on May 1, 2026 and will continue on a month-to-month basis unless terminated by either party upon 30 days' written notice.
Vancouver, British Columbia, April 20, 2026 – TheNewswire – Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces that, as a result of a review by the British Columbia Securities Commission (the “ BCSC ”), the Company is issuing the following press release to clarify recent disclosure included in the Company's LIFE offering document dated March 11, 2026 (the “ LIFE Offering Document ”, and the offering to which it relates, the “ LIFE Offering ”) and news releases dated March 13 and 18, 2026. Following the BCSC review, the Company did not qualify for the LIFE Offering and, as a result, the Company will be relying on alternate exemptions and filing an amended Report of Exempt Distribution. The securities issued under the LIFE Offering are in the process of being cancelled and re-issued with four-month restrictive holds.
Vancouver, British Columbia, March 26, 2026 – TheNewswire – Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces that the British Columbia Securities Commission (“ BCSC ”) issued an order dated March 25, 2026 under section 89(1) of the Securities Act (British Columbia) halting all trading in the Company's securities until April 16, 2026 (the “ Order ”) due to, among other matters, unexplained and unusual fluctuations in the volume of trading in, or market price, of the Company's shares traded on the CSE. The full text of the Order can be viewed on www.sedarplus.ca. The Company also wishes to clarify that the Company has not authorized, commissioned, or otherwise been involved in the creation or distribution of an article concerning the Company circulated by John Michaels on March 19, 2026 (the “ Article ”). The Company further confirms that neither the Company nor its investor relations service provider was aware of the Article prior to its publication, and neither has any relationship or affiliation with the individual or entities responsible for its authorship or dissemination. The Company did not provide information, commentary, review, approval, or input of any kind. Any statements, claims, or opinions expressed in the Article should not be construed as having been reviewed, verified, endorsed, or supported by the Company. In particular, the Article states that “the company is FDA-registered”. To the extent “FDA” refers to U.S. Food and Drug Administration, this statement is inaccurate. The Company does not have any registrations with the Food and Drug Administration, nor is actively pursuing any applications for registration for any of its products at this time. The Company refers readers to its public disclosure, which remains current, and confirms that it has no material undisclosed information at this time.
Vancouver, British Columbia – TheNewswire - March 18, 2026 – Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce that it has completed its previously announced non-brokered private placement and issued 9,625,049 units (each, a “ Unit ”) at a price of $0.24 per Unit for gross proceeds of $2,310,011.76 (the “ Offering ”). Each Unit consists of: (i) one common share of the Company and (ii) one common share purchase warrant, with each warrant entitling the holder thereof to acquire one additional common share of the Company at an exercise price of $0.30 for a period of 24 from the date of issuance.
Vancouver, British Columbia, March 16, 2026 – TheNewswire - At the request of CIRO, Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity. The Company is a biotechnology company focused on discovering and developing medications and therapies to address mental health disorders, including nicotine addiction and posttraumatic stress disorder (PTSD). The Company's objective is to use a blend of advanced technology with an elaborate infrastructure to speed up the development of breakthrough medications to provide patients with safer and more effective treatment solutions.
VANCOUVER, BC – TheNewswire - March 13, 202 6 – Noveris Health Sciences Inc. ( CSE: NVRS ) ( FSE: 0NF0 ) ( OTC: MYCOF ) (the " Company ") is pleased to announce the launch of its new investor-facing website at http://noveris.health . The website has been developed to provide shareholders, prospective investors, and other stakeholders with timely access to corporate information, investor materials, and company updates. The Company also announces that it has engaged Fairfax Partners Inc. ("Fairfax Partners"), headquartered in Vancouver, British Columbia, to provide investor relations management, communications infrastructure, and digital marketing services. The engagement for a total of up to CAD $150,000 plus applicable GST is effective March 13, 2026 and is for an initial term of three (3) months.
Vancouver, British Columbia, March 10, 2026 – TheNewswire — Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces today that Joshua Bartch has resigned as director, president and chief executive officer of the Company. The Company has appointed Jason Birmingham, who was previously appointed chief strategy officer on February 2, 2026, to assume all three positions formerly held by Mr. Bartch.
